Portfolio Fund No.1


Fund closed 2018


A simple eye scan to detect a key biomarker of Alzheimer’s disease. Optina Dx is developing a ground-breaking tool utilizing deep learning algorithms for identifying beta-amyloid (AB) plaques, a key biomarker of this disease. Learn more

Developed a diagnostic testing device capable of detecting the smallest possible number of DNA molecules in a human sample and producing an easy-to-read result in a one-step device, in a few minutes, at a cost of $10. Learn more

Pushing the limits of cancer detection by building a revolutionary proprietary platform technology based on machine learning algorithms, ODS Medical Inc. is dedicated to bringing physicians the next generation of diagnostic tools. Learn more

Advancing vein care with a first-of-its-kind replacement valve for veins. InnoVein, a Y Combinator and venture backed medical device company, is developing a first-of-its-kind valve replacement to offer patients their first definitive cure. Learn more



Optina Dx, May 08, 2019
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA. Read More:

ODS Medical, January 12, 2018
The Quebec Science magazine unveiled on Monday, March 19th the Discovery of the Year public award. It is the detection probe for cancer cells developed by Louperivois Frédéric Leblond and Kevin Petrecca, from Polytechnique Montréal and the Montreal Neurological Institute and Hospital who took home the honors. Read More:

Optina Dx, September 05, 2018
DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease. Read More

Juno Dx, March 1, 2017
CombiMatrix Appoints Molecular Diagnostics Veteran Dirk van den Boom, Ph.D. to its Board of Directors. Read More:

InnoVein, December 13, 2017
InnoVein Medical on the move. Read More:

InnoVein, July 27, 2016
Medtech's Rising Stars: Austin Walker. Read More: